Articles published by AIRNA

AIRNA Announces First Patient Dosed in Phase 1 Trial of AIR-001, Potential Best-in-Class RNA-Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

Today 7:00 EDT

From AIRNA

Via Business Wire

AIRNA Appoints Allison Dorval as Chief Financial Officer and Niru Subramanian as Chief Operating Officer

October 01, 2025

From AIRNA

Via Business Wire

AIRNA Appoints Tamara Joseph as Chief Legal Officer and Kristina Storey as Head of Regulatory Affairs

August 06, 2025

From AIRNA

Via Business Wire

AIRNA Presents Data Supporting RNA Editing Approach for Alpha-1 Antitrypsin Deficiency (AATD) at 28th ASGCT Annual Meeting

May 13, 2025

From AIRNA

Via Business Wire

AIRNA Appoints Jacob Elkins Chief Medical Officer

April 16, 2025

From AIRNA

Via Business Wire

AIRNA Raises Oversubscribed $155 Million Series B Financing to Fund Phase 1/2 Clinical Trial for Alpha-1 Antitrypsin Deficiency and Future Pipeline

April 01, 2025

From AIRNA

Via Business Wire

AIRNA Appoints Matthew Hawryluk as Chief Business Officer

January 30, 2025

From AIRNA

Via Business Wire

AIRNA Raises Oversubscribed $60 Million Financing to Advance New Class of RNA Editing Medicines and Progress Best-in-Class AATD Program into the Clinic

July 31, 2024

From AIRNA

Via Business Wire

AIRNA Launches to Develop New Class of RNA Editing Therapeutics for Rare and Common Diseases

September 19, 2023

From AIRNA

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.